Work

Phase II study of TAS-OX (TAS-102 and oxaliplatin) plus bevacizumab for late-line colorectal cancer.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.4_suppl.144

Authors: Howard S. Hochster, Hao Liu, Lyudmyla Derby Berim, Kristen Renee Spencer, Pat Gulhati, Manda DiRubbo, Seth D. Cohen, Patrick Lee, Stuart P. Leitner, Delia Radovich, Christian Misdary, Christian Perez, Sutirtha Datta, Andrea Gonzalez, Tracie Saunders, Patrick M Boland

Institutions: Rutgers Cancer Institute, Rutgers, The State University of New Jersey, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Saint Barnabas Medical Center

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4317877740

Cites:

Cited by: 1

Related to: 10